Article Text
Statistics from Altmetric.com
Recent papers in Gut have highlighted the importance of the genetic makeup and the influence of the gut microbiome on the amount of lactose in the gut in lactose-intolerant individuals.1 2 Here, we present biochemical data strongly suggesting that heterozygous carriers of certain lactase gene (LCT) variants could also be lactose-intolerant.
It is widely known that lactose malabsorption in adult-type hypolactasia (ATH) is caused by lactase downregulation beyond infancy.3 Another form of lactose intolerance is congenital lactase deficiency (CLD), a rare disease caused by biallelic LCT variants in the coding region that manifests neonatally with severe diarrhoea and dehydration after lactose ingestion with food.4 LCT encodes lactase-phlorizin hydrolase (LPH), a β-galactosidase, exclusively expressed in enterocytes and localised at the brush border membrane where it digests luminal lactose.4 Pathogenic forms of LPH elicited by LCT variants are characterised by intracellular block in the ER and complete loss of digestive activity.5 Since dimerisation of LPH monomers in the ER is an essential biosynthetic step,6 we asked whether an interaction between wild type (LPHwt) and mutant monomers (LPHmut) may occur in heterozygotes.
We therefore investigated the interaction of FLAG-tagged LPHwt with myc-tagged missense (p.G1363S-myc, p.S1124L-myc, p.S688P-myc, p.R1587H-myc) and truncated (p.E1612*, p.S1150Pfs*19, p.Y1390*) LPH mutants (see online supplemental appendix 1). All are pathogenic and severely affect function and trafficking.5 7 The potential interaction was investigated by coexpression of LPHwt and LPHmut in COS-1 cells, followed by reciprocal immunoprecipitation with anti-myc, and Western blotting with anti-FLAG or anti-LPH antibodies. As already shown, COS-1 cells, although neither intestinal nor polarised, can be used for meaningful studies of function and trafficking competence.6 8 Our data demonstrate an interaction between LPH wt and each of the full-length missense mutants (figure 1A). These LPH mut dominantly impacted trafficking with a complete block in the ER, assessed by endoglycosidase H-sensitivity indicating a mannose-rich type of glycosylation (figure 1A) and by confocal microscopy (figure 1C). Strikingly, interaction of these mutants resulted in complete loss of the digestive function of the heterodimer towards lactose (figure 1D, upper panel). In contrast, all three truncated mutants neither interacted with myc-tagged LPH wt (figure 1B) nor impacted enzymatic activity (figure 1D, lower panel).
Supplemental material
This study unequivocally demonstrates that full-length LPH mut interact efficiently with LPH wt and abolish the digestive function of resulting heterodimers, with the transmembrane domain being essential for proper dimerisation.
The question remains as to the relevance of this observation with respect to actual enzyme activity of heterozygotes. A heterozygous carrier of an LCT variant can usually be expected to have 25% of unaffected homodimers and ~25% of normal activity. Depending on effects on allosteric regulation or degradation, enzyme activities can also be significantly lower. The number of families with CLD and thus the number of known obligate heterozygotes is extremely small with 14 different LCT variants described, including only six missense variants,5 9 which may explain the current lack of information about any clinical symptoms and diet in heterozygotes.
For LPH, the clinical picture could even be complicated, if a heterozygote carried an ATH allele, a genetic variant upstream of LCT,3 on the other chromosome. Despite the high frequency of ATH worldwide, calculations on such compound heterozygosity are difficult due to large regional differences in the frequency of both ATH10 and CLD.9 Nevertheless, it should be considered in unusual forms of lactose intolerance and investigated accordingly.
In summary, we present a novel concept of a dominant-negative effect of LCT missense variants suggesting that clinical effects occur in heterozygous carriers of such variants and that clinical differentiation from ATH could be difficult and should be considered and investigated in future studies.
Ethics statements
Patient consent for publication
Ethics approval
Not applicable.
Supplementary materials
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Footnotes
DW, TS and LMM contributed equally.
RS and HYN contributed equally.
Contributors Investigation, visualisation, writing - review and editing: DW, TS, LMM. Resources, funding acquisition, writing - original, review and editing: RS. Conceptualisation, methodology, funding acquisition, writing - original, review and editing, project administration: HYN .
Funding This study has been supported by a grant from the German Research Foundation (NA331/13-1) to HYN.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.